Here at Zacks, we encourage investors to follow our proven stock-picking system, which places a great deal of emphasis on the importance of earnings estimate revisions in order to identify winning stocks. However, we also always look to cover stocks, from S&P 500 powers to small cap-firms, when they make newsworthy moves.
With that said, we understand that stocks trading at a low dollar value can become eye-catching investments. One particular group of stocks that many investors tend to pay close attention to are those currently trading for $10 per share or less.
These stocks present retail investors with the opportunity to take a large position in a company. On top of that, these stocks are also often subject to major one-day swings, which means that these under $10 stocks can be some of the biggest movers on a daily basis.
With that said, let’s take a look at three companies trading for less than $10 per share that made sizable moves on Tuesday:
Sunrun Inc. RUN
President Donald Trump approved the long-speculated tariff on imported solar cells and modules on Monday. On Tuesday, shares of several U.S. based solar energy companies saw their stock prices climb. Sunrun is a residential panel installer, and it popped over 6% as investors began to realize that Trump’s new policy might not prove as devastating to installers as previously anticipated. RUN is also a Zacks Rank #1 (Strong Buy) (also read: 3 Solar Stocks to Buy On Trump Tariff).
Inovio Pharmaceuticals, Inc. INO
One day after Inovio announced promising preliminary data for one of its drug candidates, shares of the small-cap biotech firm soared 22.63%. On Monday, Inovio released preclinical data noting that its “synthetic vaccine approach using a collection of synthetic DNA antigens generated broad protective antibody responses against all major deadly strains of H1 influenza viruses from the last 100 years.” Inovio is currently a Zacks Rank #3 (Hold) and could gain further traction if initial testing of its universal flu vaccine proves viable down the road.
NantKwest, Inc. NK
This pharmaceutical firm specializes in trying to utilize regularly produced “Natural Killer cells” to treat cancer. NantKwest’s “off-the-shelf” NK therapy has been tested in phase 1 clinical trials in the U.S., Canada, and Europe. Today, shares of this small-cap, clinical-stage immunotherapy company popped nearly 13%. Before these substantial gains, NantKwest had seen its stock price sink 26% over the last 52 weeks. However, it seems that investors might have some renewed faith in the firm after its CEO, Dr. Patrick Soon-Shiong, presented at the 36th Annual J.P. Morgan (JPM) Healthcare Conference earlier this month.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Inovio Pharmaceuticals, Inc. (INO) : Free Stock Analysis Report
NantKwest, Inc. (NK) : Free Stock Analysis Report
Sunrun Inc. (RUN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research